The University of Siena PhD Course in
Genetics, Oncology and Clinical Medicine


PhD Graduate

Marzia DEFINA  

PhD Program years: 2009 - 2012






PUBLICATIONS DURING THE PHD PROGRAM
    1) Cutaneous myeloma and bortezomib.
    Gozzetti A, Defina M, Bocchia M.
    Ann Hematol. 2009 Oct;88(10):1045.

    2) Lenalidomide on alternative days is effective in myelodysplastic syndrome with 5q- deletion.
    Defina M, Rondoni M, Gozzetti A, Aprile L, Chitarrelli I, Fabbri A, Lauria F, Bocchia M.
    Br J Haematol. 2010 Feb;148(3):483-4.

    3) Translocation(X;2)(q26;q11.2) in a patient with acute myeloid leukemia M2 evolved from essential thrombocytemia.
    Gozzetti A, Crupi R, Rondoni M, Daviddi B, Defina M, Bocchia M, Pietrini A, Raspadori D, Lauria F.
    Cancer Genet Cytogenet. 2010 Feb;197(1):84-5

    4) Hyperlipidemic myeloma.
    Gozzetti A, Defina M, Bocchia M, Lauria F.
    Ann Hematol. 2010 Sep;89(9):939-40.

    5) Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia.
    Zaja F, Baccarani M, Mazza P, Bocchia M, Gugliotta L, Zaccaria A, Vianelli N, Defina M, Tieghi A, Amadori S, Campagna S, Ferrara F, Angelucci E, Usala E, Cantoni S, Visani G, Fornaro A, Rizzi R, De Stefano V, Casulli F, Battista ML, Isola M, Soldano F, Gamba E, Fanin R.
    Blood. 2010 Apr 8;115(14):2755-62.

    6) Very late relapse in a patient with chronic myeloid leukemia in sustained complete cytogenetic response under imatinib.
    Defina M, Gozzetti A, Rondoni M, Aprile L, Ippoliti M, Chitarrelli I, Lauria F, Bocchia M. Leukemia Research. 2010 Aug;34(8):e215-6

    7) Safety and efficacy of bortezomib, melphalan and low doses dexamethasone (VM-dex) in newly diagnosed patients with multiple myeloma.
    Gozzetti A, Defina M, Bocchia M, Fabbri A, Marchini E, Chitarrelli I, Lauria F.
    Leuk Res. 2010 Nov;34(11):e288-9.

    8) Low-dose rituximab in adult patients with primary immune thrombocytopenia.
    Zaja F, Vianelli N, Volpetti S, Battista ML, Defina M, Palmieri S, Bocchia M, Medeot M, De Luca S, Ferrara F, Isola M, Baccarani M, Fanin R.
    Eur J Haematol. 2010 Oct;85(4):329-34.

    9) Reduction of imatinib dose and persistence of complete molecular response after p210 multipeptide vaccine in chronic myeloid leukaemia treated with dose escalation for acquired resistance.
    Breccia M, Bocchia M, Cannella L, Defina M, Ippoliti M, Loglisci G, Santopietro M, Lauria F, Alimena G.
    Br J Haematol. 2010 Jul;150(2):240-2.

    10) Hyperlipidemia in a myeloma patient after bortezomib treatment.
    Gozzetti A, Fabbri A, Defina M, Chitarrelli I, Bocchia M.
    Leuk Res. 2010 Sep;34(9):e250.

    11) Weekly bortezomib, pegylated liposomal doxorubicin, and dexamethasone is a safe and effective therapy for elderly patients with relapsed/refractory multiple myeloma.
    Gozzetti A, Fabbri A, Oliva S, Marchini E, Bocchia M, Defina M, Lauria F.
    Clin Lymphoma Myeloma Leuk. 2010 Feb;10(1):68-72.

    12) A der(1)t(1;21)(p36.3;q22) in a patient with acute myelogenous leukemia M2.
    Gozzetti A, Crupi R, Rondoni M, Defina M, Bocchia M, Pietrini A, Raspadori D, Lauria F.
    Acta Haematol. 2010;124(1):44-5. Epub 2010 Jul 3.

    13) Complete molecular response in CML after p210 BCR-ABL1-derived peptide vaccination.
    Bocchia M, Defina M, Aprile L, Ippoliti M, Crupi R, Rondoni M, Gozzetti A, Lauria F.
    Nat Rev Clin Oncol. 2010 Oct;7(10):600-3.

    14) Lenalidomide efficacy in bortezomib-resistant myeloma.
    Gozzetti A, Crupi R, Defina M, Bocchia M.
    Nat Rev Clin Oncol. 2010 Sep;7(9).

    15)Unusual localizations of plasmacytoma.
    Gozzetti A, Coviello G, Fabbri A, Della Corte R, Bocchia M, Defina M, Lauria F.
    Leuk Res. 2011 Jul;35(7):e104-5.

    16) A central nervous system CD56 positive multiple myeloma patient with a t(11;14) (q11;q32): a case report.
    Gozzetti A, Cerase A, Crupi R, Raspadori D, Defina M, Bocchia M, Lauria F.
    Leuk Res. 2011 Nov;35(11):e206-8.

    17) Extramedullary multifocal plasmacytoma relapse in multiple myeloma.
    Gozzetti A, Marchini E, Banchi B, Papini G, Defina M, Bocchia M, Lauria F.
    Leuk Res. 2012 Jan;36(1):e34-6.
    18) Plasmacytoma of the skull.
    Gozzetti A, Cerase A, Defina M, Bocchia M.
    Eur J Haematol. 2012 Apr;88(4):369.

    19) Efficacy of bortezomib, lenalidomide and dexamethasone (VRD) in secondary plasma cell leukaemia.
    Gozzetti A, Musto P, Defina M, D'Auria F, Papini G, Steduto T, D'Arena G, Bocchia M.
    Br J Haematol. 2012 Feb 1.

    20) Evaluation of residual CD34+Ph+ progenitor cells in chronic myeloid leukemia patients in complete cytogenetic response during first line nilotinib therapy. Marzia Defina, Micaela Ippoliti, Alessandro Gozzetti, Elisabetta Abruzzese, Fausto Castagnetti, Rosaria Crupi, Mario Tiribelli, Massimo Breccia, Marzia Salvucci, Lara Aprile, Claudia Baratè, Antonella Gozzini, Gianantonio Rosti, Francesco Lauria and Monica Bocchia. Cancer. 2012. In press

    21) Extramedullary myeloma relapses.
    Gozzetti A, Papini G, Defina M, Bocchia M.
    Ann Hematol. 2012 Feb 25.

ABSTRACTS OF CONFERENCE DURING THE PHD PROGRAM

1. Evaluation of residual CD34+/Ph+ stem cells in chronic myeloid leukemia patients in complete cytogenetic response during front line nilotinib therapy Defina M, Ippoliti M, Abruzzese E, Castagnetti F, Tiribelli M, Rosti G, Breccia M, Trawinska MM, Crupi R, Aprile L, Salvucci M, Baratè C, Gozzini A, Rondoni M, Zaccaria A, Alimena G, Santini V, Specchia G, Fanin R, Gozzetti A, Baccarani M, Lauria F, Bocchia M. Haematologica. 43° Congress of the Italian Society of Hematology. 16-19 October 2011, Naples, Italy.

2. Azacitidine Low-Dose Schedule In Low-Risk Myelodysplastic Syndromes. Preliminary Results of a Multicenter Phase II Study. Carla Filì, Carlo Finelli, Marco Gobbi, Giovanni Martinelli, Ilaria Iacobucci, Emanuela Ottaviani, Lucio Cocco, Matilde Follo, Anna Candoni, Erika Simeone, Maurizio Miglino, Francesco Lauria, Monica Bocchia, Marzia Defina, Cristina Clissa, Francesco Lanza, Antonio Curti, Stefania Paolini, PierAngelo Spedini, Cristina Skert, Cesare Bergonzi, Michele Malagola, Annalisa Peli, Alessandro Turra, Federica Cattina, Chiara Colombi, and Domenico Russo. Blood (ASH Annual Meeting Abstracts), Nov 2010; 116: 4029.

3. Evaluation of Residual CD34+/Ph+ Stem Cells In Chronic Myeloid Leukemia Patients In Complete Cytogenetic Response during First Line Nilotinib Therapy. Monica Bocchia, Marzia Defina, Micaela Ippoliti, Elisabetta Abruzzese, Fausto Castagnetti, Mario Tiribelli, Gianantonio Rosti, Massimo Breccia, Malgorzata Monika Trawinska, Rosaria Crupi, Lara Aprile, Marzia Salvucci, Claudia Baratè, Antonella Gozzini, Michela Rondoni, Alfonso Zaccaria, Giuliana Alimena, Valeria Santini, Giorgina Specchia, Renato Fanin, Alessandro Gozzetti, and Francesco Lauri. Blood (ASH Annual Meeting Abstracts), Nov 2010; 116: 3413.

4. Long-lasting p210 peptide vaccine treatment in chronic myeloid leukemia patients: safety profile and clinical results. Defina M. Ippoliti M, Gozzetti A. Crupi R, Aprile L, Tassi M, Rondoni M, Lauria F, Bocchia M. Haematologica. 15th Congress of the European Hematology Association. Barcellona, Spain, June 10-13, 2010

5. Identification of a novel p190-derived breakpoint peptide suitable for peptide vaccine therapeutic approach in Ph+ acute lymphoblastic leukemia patients. Ippoliti M, Defina M, Aprile L, Gozzetti A, Crupi R, Tassi M, Rondoni M, Lauria F, Bocchia M. XI National SIES meeting. Turin, Italy, October 6-8, 2010.

6. BCR-ABL Derived Peptide Vaccine in Chronic Myeloid Leukemia Patients with Molecular Minimal Residual Disease During Imatinib: Interim Analysis of a Phase 2 Multicenter GIMEMA CML Working Party Trial. Monica Bocchia, Marzia Defina, Micaela Ippoliti, Marilina Amabile, Massimo Breccia, Francesco Iuliano, Marco Vignetti, Gabriele Gugliotta, Antonella Russo Rossi, Giuliana Alimena, Lara Aprile, Gianluca Gaidano, Paolo Nicoli, Malgorzata Monika Trawinska, Renato Bassan, Diamante Turri, Laura Cannella, Luigia Luciano, Alessandro Gozzetti, Michela Rondoni, Gianantonio Rosti, Giovanni Martinelli, Michele Baccarani, and Francesco Lauria. Blood (ASH Annual Meeting Abstracts), Nov 2009; 114: 648.

7. Long Term Follow up Analysis Following Front Line Therapy with Dexamethasone or Dexamethasone Plus Rituximab in Adults with Primary Immune Thrombocytopenia. Francesco Zaja, Michele Baccarani, Patrizio Mazza, Nicola Vianelli, Monica Bocchia, Marzia Defina, Luigi Gugliotta, Alessia Tienghi, Sergio Amadori, Selenia Campagna, Felicetto Ferrara, Mariacarla De Simone, Alfonso Zaccaria, Anna Lia Molinari, Emanuele Angelucci, Emilio Usala, Silvia Cantoni, Antonella Fornaro, Giuseppe Visani, Rita Rizzi, Valerio De Stefano, Francesco Casulli, Marta Battista, Miriam Isola, Franca Soldano, and Renato Fanin. Blood (ASH Annual Meeting Abstracts), Nov 2009; 114: 2415.

8. Four Drugs Combination (Fludarabine, Cytarabine, Idarubicin, Etoposide) as Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia Patients Younger Than 65 Ys: Response and Follow-up of 84 Patients.
Michela Rondoni, Michele Malagola, Stefania Paolini, Marzia Defina, Pier Paolo Piccaluga, Lara Aprile, Cristina Papayannidis, Nicoletta Testoni, Rosaria Crupi, Alessandro Gozzetti, Monica Tozzi, Giuseppe Marotta, Francesca Toraldo, Domenico Russo, Monica Bocchia, Michele Baccarani, Giovanni Martinelli, and Francesco Lauria
Blood (ASH Annual Meeting Abstracts), Nov 2009; 114: 4147.

9. Clinical and Biological EFFECTS of 5-Azacitidine FIVE Days/Monthly Schedule IN Symptomatic LOW-RISK (IPSS: 0-1) Myelodisplastic Patient.
Carla Filí, Marco Gobbi, Giovanni Martinelli, Carlo Finelli, Ilaria Iacobucci, Emanuela Ottaviani, Lucio Cocco, Matilde Y Follo, Anna Candoni, Erica Simeone, Maurizio Miglino, Francesco Lauria, Monica Bocchia, Marzia Defina, Cristina Clissa, Cristina Skert, Cesare Bergonzi, Michele Malagola, Aldo M. Roccaro, Annalisa Peli, Alessandro Turra, Chiara Colombi, and Domenico Russo
Blood (ASH Annual Meeting Abstracts), Nov 2009; 114: 4851

10. Response to Dasatinib in patients with sistemi mastocytosis with D816V kit mutation: 9 italian cases. Rondoni M, Paolini S, Colarossi S, Fabbri A, Pregno P, Piccaluga PP, Galimberti S, Baratè C, Papayannidis C, Defina M, Soverini S, Lauria F, Baccarani M, Martinelli G. Haematologica. 42° Congress of the Italian Society of Hematology. 18-21 October 2009, Milan, Italy.

11. Low dose Rituxiamb as salvage therapy in adult patients with primary immune thrombocytopenia. Zaja F, Battista ML, Defina M, Vianelli N, Palmieri S, Bocchia M, Medeot M, Volpetti S, De Luca S, Ferrara F, Isola M, Baccarani M, Fanin R. Haematologica. 42° Congress of the Italian Society of Hematology. 18-21 October 2009, Milan, Italy.

12. Bortezomib, pegylate liposomal doxorubicin and dexamethasone (B-PLD-D) as therapy for elderly patients with relapsed refractory multiple myeloma: a weekly bortezomib infusion schedule reduces toxicities maintaining the same efficacy. Gozzetti A, Fabbri A, Oliva S, Marchini E, Bocchia M, Defina M, Lauria F. Haematologica. 42° Congress of the Italian Society of Hematology. 18-21 October 2009, Milan, Italy.

13. Clinical and biological effects of 5-azacitidine five days/monthly schedule in symptomatic low-risk (IPSS: 0-1) myelodisplastic patients. Filì C, Bergonzi C, Skert C, Malagola M, Roccaro AM, Peli A, Turra A, Colombi C, Cattina F, Martinelli G, Finelli C,Clissa C, Iacobucci I, Ottaviani E, Cocco L, Follo MY, Candoni A, Simeone E, Gobbi M, Miglino M, Lauria F, Bocchia M, Defina M, Russo D. Haematologica. 42° Congress of the Italian Society of Hematology. 18-21 October 2009, Milan, Italy.
ACTIVITY DURING THE PHD PROGRAM

TRAINING PERIOD ABROAD
  • Hosting Institution Name
    Location
    Period dates

  • Hosting Institution Name
    Location
    Period dates